Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre-existing cardiovascular disease. These attribute...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2021-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|